All In MedTech

FDA Clearance Tracker · P900033-S053

INTEGRA(R) DERMAL REGENERATION TEMPLATE, INTEGRA(R) MESHED DERMAL REGENERATION TEMPLATE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 9, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 9, 2016

Approved

Time to decision

188 days

Received Nov 3, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P900033-S053
Device name
INTEGRA(R) DERMAL REGENERATION TEMPLATE, INTEGRA(R) MESHED DERMAL REGENERATION TEMPLATE
Applicant location
Plainsboro, NJ
Received
Nov 3, 2015
Decided
May 9, 2016
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P900033

Device type

Device class
Class III

Every decision under product code MDD

FDA's approval statement

As written in FDA's record.

Approval of two new product sizes (i.e., 4cm x 4cm and 7cm x 7cm) and revised packaging that permits inclusion of a stapler and staples in the Integra Omnigraft Dermal Regeneration Matrix kit. The device, as modified, will be marketed under the trade name Omnigraft Dermal Regeneration Matrix.

Source documents

Other decisions for Integra Lifesciences Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

4 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.